Tracon Pharmaceuticals, Inc.
TCONDelisted Jul 19, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001394319
Tracon Pharmaceuticals, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Mar 13, 2024; 29 institutions reported holding it in 13F filings for Q1 2024, worth $1.39M in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Tracon Pharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −6 vs. Q2 2023
- Shares held
- 9.31M
- −647.1K (−6.5%) vs. Q2 2023
- Total value
- $1.66M
- −$1.24M (−42.8%) vs. Q2 2023
- New holders
- 2
- 3 more added
- Sold out
- 8
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TCON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 29 | $1.39M |
| Q4 2023 | 24 | $903.4K |
| Q3 2023 | 21 | $1.66M |
| Q2 2023 | 27 | $2.90M |
| Q1 2023 | 32 | $18.8M |
| Q4 2022 | 32 | $14.6M |
| Q3 2022 | 33 | $16.5M |
| Q2 2022 | 31 | $19.7M |
| Q1 2022 | 35 | $24.0M |
| Q4 2021 | 35 | $25.4M |
| Q3 2021 | 45 | $39.6M |
| Q2 2021 | 44 | $58.5M |
| Q1 2021 | 42 | $72.8M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Tracon Pharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Opaleye Management Inc. | 4,764,508 | $848.1K | 0.28% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 2,765,530 | $492.3K | 0.18% | 00.0% | Unchanged |
| Vanguard Group Inc | 619,740 | $110.3K | 0.00% | −123,348−16.6% | Reduced |
| BlackRock Inc. | 267,821 | $47.7K | 0.00% | +1020.0% | Added |
| Boothbay Fund Management, LLC | 258,844 | $46.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 213,223 | $38.0K | 0.00% | +57,397+36.8% | Added |
| Renaissance Technologies LLC | 134,538 | $24.0K | 0.00% | −8,946−6.2% | Reduced |
| Johnson & Johnson | 84,003 | $15.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 75,154 | $13.4K | 0.00% | 00.0% | Unchanged |
| CI Private Wealth, LLC | 57,455 | $10.2K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 21,691 | $3.86K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 15,835 | $2.82K | 0.00% | +15,835 | New |
| Hoylecohen, LLC | 13,000 | $2.31K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 10,407 | $1.85K | 0.00% | −29−0.3% | Reduced |
| Bank of New York Mellon Corp | 10,259 | $1.83K | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 318 | $57 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 311 | $55 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 176 | $31 | 0.00% | +13+8.0% | Added |
| JPMorgan Chase & Co | 21 | $4 | 0.00% | +21 | New |
| Royal Bank of Canada | 264 | $0 | 0.00% | −7−2.6% | Reduced |
| Cutler Group LP | 1,200 | $0 | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 0 | $0 | 0.00% | −454,916−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −49,165−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −28,362−100.0% | Sold out |
| Charles Schwab Investment Management Inc | 0 | $0 | 0.00% | −22,638−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −21,169−100.0% | Sold out |
| We Are One Seven, LLC | 0 | $0 | 0.00% | −11,780−100.0% | Sold out |
| ICA Group Wealth Management, LLC | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |